|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 276.4 USD | +2.37% |
|
+1.64% | -4.04% |
| 08:03am | Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation | DJ |
| 07:51am | Sandoz Group Settles Patent Disputes with Amgen | MT |
Dec 26 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined to grant traditional approval to Amgen's Lumakras for treating lung cancer patients with a specific gene mutation, but did not withdraw the drug's existing accelerated approval status.
Lumakras was approved by the FDA in 2021 under an accelerated pathway, with confirmatory data a condition for gaining traditional approval.
(Reporting By Deena Beasley and Manas Mishra in Bengaluru; Editing by Bill Berkrot)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 276.4 USD | +2.37% | +1.64% | 148B | ||
| 44.64 USD | -0.47% | -9.16% | 90.49B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -4.04% | 148B | |
| +26.47% | 664B | |
| +26.13% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +13.49% | 234B | |
| +4.71% | 199B | |
| -10.02% | 196B | |
| -10.94% | 145B |
AMGEN INC. 
